# Senseonics Holdings, Inc. (SENS)

> Source: Nexqual · https://nexqual.com/SENS · data as of 2026-10-23 17:39 UTC · cite as "Nexqual, Senseonics Holdings, Inc. (SENS), nexqual.com/SENS" · informational, not investment advice.

**Price:** USD 7.58 (+2.36% today) · US market open, as of October 23, 2026 at 17:39 UTC; quotes may be delayed. Prev close 7.4 · day 7.25–7.59 · 52w 4.79–10.64 · market cap $401M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $48.5M, net income -$109M (-225.3% margin), free cash flow -$96.8M (SEC filings).
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $251K; 2 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y +3.1% vs S&P 500 +14.4%; 5Y -89.2% vs S&P 500 +77.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.52, revenue estimate $16.2M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $13.7M | $16.4M | $22.4M | $22.5M | $35.3M | $48.5M |
| Gross profit | -$811K | $2.7M | $3.1M | $533K | $15.8M | — |
| Operating income | -$57.2M | -$68.6M | -$75.6M | -$74.8M | -$68.3M | -$108M |
| Net income | -$302M | $142M | -$60.4M | -$78.6M | -$69.1M | -$109M |
| EPS (diluted) | -$14.40 | -$2.20 | -$2.20 | -$2.50 | -$1.66 | — |
| Free cash flow | -$56.3M | -$66.6M | -$70.5M | -$62.7M | -$60.2M | -$96.8M |
| Gross margin | -5.9% | 16.6% | 13.8% | 2.4% | 44.7% | — |
| Operating margin | -418.1% | -418.7% | -337.7% | -333.0% | -193.8% | -223.2% |
| Net margin | -2211.9% | 867.2% | -269.7% | -349.8% | -196.0% | -225.3% |
| Revenue growth | +176.3% | +19.8% | +36.6% | +0.4% | +56.9% | — |
| Cash + short-term investments | $182M | $156M | $110M | $74.6M | $94.0M | — |
| Total debt | $59.8M | $56.4M | $41.2M | $34.7M | $35.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 8.3x · EV/Sales 6.5x · P/B 4.4x · FCF yield -24.18% · Earnings yield -27.31% · Net cash $86.9M · EV $314M

## Insider purchases (SEC Form 4, open-market, last ~7 months)
2 purchases, $251K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-19 | Roeder Douglas A | Director | 13,953 | $125K | 8.98 | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-12 | Roeder Douglas A | Director | 22,686 | $126K | 5.56 | Opportunistic (traded every year 2023–2025, no repeating month) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $10 |
| 2026-07-15 | Mizuho | Target lowered | Outperform | $20 → $18 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +3.1% | -89.2% |
| S&P 500 (SPY) | +14.4% | +77.1% |
| Per year | +3.1% | -35.9% |
| Volatility (annualized) | 77.6% | 86.9% |
| Max drawdown | -41.8% (Feb 2026→Jul 2026) | -93.7% (Nov 2021→Jul 2026) |

## Peers (Medical Devices)
ATEC (Alphatec Holdings, Inc.) USD 11.26 -0.88% · BFLY (Butterfly Network, Inc.) USD 6.7 -1.59% · ESTA (Establishment Labs Holdings Inc) USD 64.44 +1.45% · INSP (Inspire Medical Systems, Inc.) USD 70.89 -2.44% · ALMR (Alamar Biosciences, Inc.) USD 30.86 +3.84% · AXGN (AxoGen, Inc.) USD 37.7 +2.77%

## More
Full page: https://nexqual.com/SENS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in SENS's own 10-K filed 2026-03-02 (https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Ascensia Diabetes Care Holdings | "As described in detail below, in August 2020, we entered into a collaboration and commercialization agreement ("Commercialization Agreement"), with Ascensia pursuant to which we granted Ascensia the exclusive right to di…" |
| Partner | Hercules Capital, Inc. (HTGC) | "On September 8, 2023, the Company entered into the "Loan and Security Agreement with Hercules Capital, Inc. and its managed fund (collectively, the "Lenders"), pursuant to which the Lenders have to make available to Sens…" |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $12.6M | 86.8% | +154.2% |
| Non Us | $1.9M | 13.2% | +12.2% |
| Total revenue | $14.5M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 57.7%, 12.5% of revenue from unnamed direct customers (10-Q, filed 2026-08-06).

## Company outlook (8-K filed 2026-08-06)

- "Senseonics is raising its full-year 2026 global net revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%, and is raising its full-year gross margin guidance to a range of 58% to 61% from its prior range of 55% to 58%."
- "The Company's outlook continues to reflect the ongoing roll-out of Eversense 365 outside the United States, planned direct-to-consumer marketing investment, the status of other sales and marketing initiatives, and utilization of the patient assistance programs for Eversense 365."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.52 | $-0.60 | -13.3% | $16.2M | 7 |
| Next quarter (ends 2026-12-31) | $-0.46 | $-0.55 | -16.2% | $21.8M | 7 |
| Current fiscal year (ends 2026-12-31) | $-2.29 | $-2.45 | -6.7% | $64.2M | 7 |
| Next fiscal year (ends 2027-12-31) | $-1.95 | $-2.19 | -10.8% | $100.0M | 7 |